InspireMD Q3 revenue +8.8% to $1.56M; CMS expands CAS coverage; trial results positive

InspireMD, Inc.

2023-Q3 EPS reported -$0.69 revenue$4,444,000

Q3 revenue $1.556M (+8.8% YoY); gross margin 28.1% (vs 25.6% Q3 2022).
Net loss $5.178M ($0.15/diluted share) vs $4.529M ($0.58) in Q3 2022; cash $43.0M.
Positive 30-day C-GUARDIANS IDE results: major adverse events (death/stroke/MI) rate 0.95% at VIVA23.
CMS final NCD expanded CAS coverage to asymptomatic & standard risk patients, broadening addressable market.
Leadership additions: Patrick Verta EVP Clinical, Cheryl Tal VP QA/RA; Shane Gleason promoted to CCO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

InspireMD, Inc. reported financial results for three and nine months ended September 30, 2023.

Period: three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039434

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.